HER-2 - A Possible Target for Therapy of Metastatic Urinary Bladder Carcinoma

Authors

  • Kenneth Wester From the Division of Experimental Urology, Department of Surgical Sciences (K. Wester), Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology (A. Sjo stro m, J. Carlsson), Division of Pathology, Department of Genetics and Pathology (M. De La Torre), Division of Urology, Department of Surgical Sciences (P.-U. Malmstro m), Uppsala University, Uppsala, Sweden
  • Anna Sjöström From the Division of Experimental Urology, Department of Surgical Sciences (K. Wester), Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology (A. Sjo stro m, J. Carlsson), Division of Pathology, Department of Genetics and Pathology (M. De La Torre), Division of Urology, Department of Surgical Sciences (P.-U. Malmstro m), Uppsala University, Uppsala, Sweden
  • Manuel De La Torre From the Division of Experimental Urology, Department of Surgical Sciences (K. Wester), Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology (A. Sjo stro m, J. Carlsson), Division of Pathology, Department of Genetics and Pathology (M. De La Torre), Division of Urology, Department of Surgical Sciences (P.-U. Malmstro m), Uppsala University, Uppsala, Sweden
  • Jörgen Carlsson From the Division of Experimental Urology, Department of Surgical Sciences (K. Wester), Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology (A. Sjo stro m, J. Carlsson), Division of Pathology, Department of Genetics and Pathology (M. De La Torre), Division of Urology, Department of Surgical Sciences (P.-U. Malmstro m), Uppsala University, Uppsala, Sweden
  • Per-Uno Malmström From the Division of Experimental Urology, Department of Surgical Sciences (K. Wester), Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology (A. Sjo stro m, J. Carlsson), Division of Pathology, Department of Genetics and Pathology (M. De La Torre), Division of Urology, Department of Surgical Sciences (P.-U. Malmstro m), Uppsala University, Uppsala, Sweden

DOI:

https://doi.org/10.1080/02841860260088836

Abstract

Human epidermal growth factor receptor 2, HER-2, is overexpressed in various tumours, e.g. breast- and bladder tumours. The aim of this study was to predict the potential use of HER-2 receptors as targets in systemic treatment of disseminated bladder tumours. HER-2 expression was assessed in bladder carcinoma metastases and the corresponding primary tumours, and subsequently compared with the EGFR expression. HER-2 and EGFR expression was analysed by immunohistochemistry in formalin-fixed, paraffin-embedded tissues from 21 patients with metastatic bladder carcinoma. HER-2 was overexpressed in 81% of the primary tumours and in 67% of the metastases. All HER-2-positive metastases were from HER-2-positive primary tumours. The results for EG FR were 71% of both primary and metastases-positive tumours. In 90% of the primary tumours and 86% of the metastases, at least one of the receptors was overexpressed. These results suggest that HER-2 targeted therapy can be considered as an alternative or a complement to other modalities in the treatment of metastatic urinary bladder carcinoma.

Downloads

Download data is not yet available.

Downloads

Published

2002-01-01

How to Cite

Wester, K., Sjöström, A., De La Torre, M., Carlsson, J., & Malmström, P.-U. (2002). HER-2 - A Possible Target for Therapy of Metastatic Urinary Bladder Carcinoma. Acta Oncologica, 41(3), 282–288. https://doi.org/10.1080/02841860260088836

Issue

Vol. 41 No. 3 (2002): Acta Oncologica

Section

Articles